Healthcare Equipment and Supplies
Company Overview of Arch Therapeutics, Inc.
Arch Therapeutics, Inc. operates as a life science medical device company. The company focuses on developing products by utilizing a novel approach to stop bleeding and control leaking during surgery and trauma care. Its lead product candidate includes AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide, which comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Wellesley, Massachusetts.
20 William Street
Wellesley, MA 02481
Founded in 2006
Key Executives for Arch Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $402.0K
Chief Financial Officer and Treasurer
Total Annual Compensation: $267.5K
Compensation as of Fiscal Year 2015.
Arch Therapeutics, Inc. Key Developments
Arch Therapeutics, Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 03:30 PM
Sep 24 15
Arch Therapeutics, Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 03:30 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Terrence W. Norchi, Co-Founder, Chief Executive Officer, President and Director.
Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device in Preclinical Toxicity Test of Sensitization
Sep 8 15
Arch Therapeutics, Inc. obtained favorable data from a preclinical toxicology test for AC5™ showing that the device did not cause sensitizing reactions in animals and is considered a 'non-sensitizer'. The test, called the Maximization Test, is a standardized test of contact sensitization and is performed in animals as a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5 is a development-stage hemostasis product being evaluated to control bleeding, mitigate fluid loss, and create an environment permissive to normal healing in order to provide more efficient surgical and interventional care. In this standard in vivo study, designed to provide general information on the health hazards likely to arise from acute exposure to clinically relevant quantities of AC5, AC5 was well tolerated when using standardized success criteria based upon comparison with control materials. As a result, AC5 was classified as a non-sensitizer with no evidence of causing delayed contact sensitization. Results from this biocompatibility safety study indicate that AC5’s peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound site, does not promote sensitization to the overall biological system following application of standardized AC5 extract solutions in animals. The results of this study provide further evidence of the absence of toxicity for AC5, and represent a critical step toward demonstrating biocompatibility of this medical device.
Arch Therapeutics, Inc. Appoints James Sulat as Director
Aug 20 15
Arch Therapeutics, Inc. has appointed James Sulat to its board of directors as an independent member, effective August 19, 2015. Mr. Sulat served as chief executive officer and chief financial officer of Maxygen Inc. from October 2009 to June 2013. Prior to this, he was chief executive officer, chief financial officer and a member of the board of directors at Memory Pharmaceuticals Corp. from 2005 to 2008. He previously served in senior executive roles for R.R. Donnelley & Sons Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. He currently serves as chairman of the board of directors of Momenta Pharmaceuticals, Inc. He has additionally served on numerous boards including Valneva SE, AMAG Pharmaceuticals, Inc., diaDexus, Inc., and General Surgical Innovations, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 22, 2015
March 11, 2015